Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Expensify And 2 Other Stocks Under $2 Insiders Are Buying

Author: Avi Kapoor | June 04, 2024 07:24am

The Dow Jones index closed lower by over 100 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

Expensify

  • The Trade: Expensify, Inc. (NASDAQ:EXFY) Director Timothy L Christen bought a total of 19,162 shares at an average price of $1.61. To acquire these shares, it cost around $30,851.
  • What's Happening: On May 9, Expensify posted downbeat quarterly results.
  • What Expensify Does: Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money.

Bio Essence

  • The Trade: Bio Essence Corporation (OTC:BIOE) CEO Yin Yan acquired a total of 5,000,000 shares at an average price of $0.50. To acquire these shares, it cost around $2.5 million.
  • What's Happening: The company’s stock jumped around 127% over the past month.
  • What Bio Essence Does: Bio Essence Corp is an herbal health, diet, and nutrition company. The Company’s mission is to provide herbal health, diet, and vitamin nutritional supplements.

Perspective Therapeutics

  • The Trade: Perspective Therapeutics, Inc. (NASDAQ:CATX) CFO Jonathan Robert Hunt acquired a total of 25,006 shares at an average price of $1.40. The insider spent around $35,007 to buy those shares. The company's Director Robert F Williamson III also bought 55,000 shares of the company.
  • What's Happening: On May 24, Perspective Therapeutics announced the pricing of $80 million underwritten offering of common stock and pre-funded warrants.
  • What Perspective Therapeutics Does: Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body.

Now Read This: Top 3 Utilities Stocks That May Plunge In Q2

Posted In: BIOE CATX EXFY